Related Experiment Video
Updated: Oct 4, 2026

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells
M Düfer1, P Krippeit-Drews, N Lembert
1Department of Pharmacology, Institute of Pharmacy, University of Tübingen, Tübingen, Germany.
Abstract:
Treatment of patients after organ transplantation with the immunosuppressive drug cyclosporin A (CsA) is often accompanied by impaired glucose tolerance, thus promoting the development of diabetes mellitus. In the present article we show that 2 to 5 microM CsA diminishes glucose-induced insulin secretion of isolated mouse pancreatic islets in vitro by inhibiting glucose-stimulated oscillations of the cytoplasmic free-Ca(2+) concentration [Ca(2+)](c). This effect is not due to an inhibition of calcineurin, which mediates the immunosuppressive effect of CsA, because other calcineurin inhibitors, deltamethrin and tacrolimus, did not affect the oscillations in [Ca(2+)](c) of the B-cells. The CsA-induced decrease in [Ca(2+)](c) to basal values was not caused by a direct inhibition of L-type Ca(2+) channels. CsA is known to be a potent inhibitor of the mitochondrial permeability transition pore (PTP), which we recently suggested to be involved in the regulation of oscillations. Consequently, CsA also inhibited the oscillations of the cell membrane potential, and it is shown that these effects could not be ascribed to cellular ATP depletion. However, the mitochondrial membrane potential Delta Psi was affected by CsA by inhibiting the oscillations in Delta Psi. Interestingly, the observed reduction in [Ca(2+)](c) could be counteracted by the K(+)(ATP) channel blocker tolbutamide, indicating that the stimulus-secretion coupling was interrupted before the closure of K(+)(ATP) channels. It is concluded that CsA alters B-cell function by inhibiting the mitochondrial PTP. This terminates the oscillatory activity that is indispensable for adequate insulin secretion. Thus, CsA acts on different targets to induce the immunosuppressive and the diabetogenic effect.
Insights
Cyclosporin A (CsA) impairs glucose tolerance by disrupting pancreatic B-cell function. CsA inhibits mitochondrial permeability transition pores, halting calcium oscillations essential for insulin secretion and leading to diabetes.
Area of Science:
- Endocrinology
- Cell Biology
- Pharmacology
Background:
- Organ transplant patients on cyclosporin A (CsA) often develop impaired glucose tolerance and diabetes.
- The exact mechanism by which CsA induces diabetogenic effects remains incompletely understood.
Purpose of the Study:
- To investigate the in vitro effects of CsA on glucose-induced insulin secretion in mouse pancreatic islets.
- To elucidate the cellular mechanisms underlying CsA-induced impairment of B-cell function.
Main Methods:
- Isolated mouse pancreatic islets were treated with CsA (2-5 microM).
- Measurements included glucose-induced insulin secretion, cytoplasmic free Ca(2+) concentration ([Ca(2+)](c)) oscillations, and cell membrane potential.
- Effects were compared with other calcineurin inhibitors and assessed for ATP depletion and mitochondrial membrane potential (Delta Psi) changes.
Main Results:
- CsA (2-5 microM) diminished glucose-induced insulin secretion by inhibiting [Ca(2+)](c) oscillations in pancreatic B-cells.
- This effect was independent of calcineurin inhibition and direct L-type Ca(2+) channel blockade.
- CsA inhibited mitochondrial permeability transition pore (PTP) and mitochondrial membrane potential oscillations, but not cellular ATP levels.
Conclusions:
- CsA impairs pancreatic B-cell function by inhibiting the mitochondrial PTP, disrupting calcium oscillations necessary for insulin secretion.
- This mechanism explains the diabetogenic side effects of CsA in transplant patients.
- CsA targets distinct pathways for its immunosuppressive and diabetogenic actions.
Related Concept Videos
Type I Diabetes II: Pathophysiology
Type II Diabetes II: Pathophysiology
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type I Diabetes I: Introduction
Inhibition of Cdk Activity
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...